EVT Evotec SE

2.994USD2.730 EUR · XETRA+0.07%Mkt Cap: 532.06M USDP/E: —

Evotec SE operates as a drug discovery and development company in the United States, Germany, France, the United Kingdom, Switzerland, and internationally. It operates in two segments, Shared R&D and Just – Evotec Biolog…

Institutional holders11 on file

Key Statistics

Company
Market Cap532.06M USD
Enterprise Value620.86M USD
Revenue (TTM)787.86M USD
Gross Profit125.28M USD
Net Income (TTM)-113.54M USD
Revenue/Share4.44 USD
Last Price2.994 USD
Fiscal Year EndDec 2025
MR QuarterSep 2026
Employees4.4K
CountryDE
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
ISINDE0005664809
Valuation
P/E (Trailing)—
P/E (Forward)-5.98
PEG1.43
EV/EBITDA-9.47
EV/Revenue0.79
P/S0.68
P/B0.76
EPS (TTM)-1.11 USD
EPS (Forward)-0.50 USD
52W Range
2.6397% of range7.381
52W High7.381 USD
52W Low2.639 USD
Profitability
Gross Margin14.49%
Oper. Margin-17.96%
EBITDA Margin-8.32%
Profit Margin-13.13%
ROE-12.72%
ROA-6.04%
ROIC-6.99%
ROCE-4.15%
Growth
Revenue Growth0.60%
Earnings Growth—
Cash Flow & Leverage
Operating CF-10.07M USD
CapEx (TTM)90.62M USD
FCF Margin29.06%
FCF Yield43.02%
Net Debt88.71M USD
Net Debt/EBITDA-1.35
Net Debt/FCF0.39
Balance Sheet
Debt/Equity0.55
Current Ratio2.32
Quick Ratio2.00
Book Value/Sh3.96 USD
Cash/Share2.47 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split2:1
Split DateAug 18, 2000
Analyst Consensus
Rating2.5 (Hold)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)4.113 USD
Upside (mean)+37.4%
Target Range3.290 USD – 5.484 USD
3.290+37.4% to mean5.484
# Analysts7
Ownership
Shares Out.177.69M
Float147.01M
Insiders9.97%
Institutions47.61%
Technical
SMA 503.139 (-4.6%)
SMA 2004.548 (-34.2%)
Beta1.31
S&P 52W Chg12.00%
Avg Vol (30d)1.24M
Avg Vol (10d)1.26M
Technical Indicators
RSI (14)39.9
MACD-0.0077
MACD Signal0.0260
MACD Hist.-0.0337
BB Upper3.550 USD
BB Middle3.217 USD
BB Lower2.885 USD
BB Width20.65%
ATR (14)0.1608 USD
Vol Ratio (20d)1.23x

About Evotec (ETR: EVT)

›

Evotec (ETR: EVT) is listed on Xetra (Frankfurt), where its shares trade in EUR. It belongs to the Drug Manufacturers - Specialty & Generic industry, part of the Healthcare sector, and reports about 4,379 employees.

The shares were at 2.730 EUR on 19 November 2026, down 47.6% over 52 weeks. Its 52-week range is 2.406 EUR to 6.730 EUR: the price is 59.4% below the high and 13.5% above the low.

Its market capitalisation is 485.11M EUR.

Evotec reports return on equity of -12.7%, an operating margin of -18.0% and revenue up 0.6% year over year.

Its debt exceeds its cash by 80.88M EUR, a debt-to-equity ratio of 0.55. Its Piotroski F-score is 6 out of 9, an average reading of its financial health. 7 analysts cover the stock, with an average rating of Hold; their mean price target of 3.750 EUR is 37.4% above the current price. The next earnings report is expected on 7 April 2027.